CeriBell, Inc., was incorporated in Delaware on August 29, 2014. They are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with severe neurological diseases. They developed the Ceribell System, a novel point-of-care electroencephalography (" EEG ") platform specifically designed to address the unmet needs of patients in acute care settings. The Ceribell system combines proprietary, highly portable, rapidly deployable hardware with sophisticated artificial intelligence (" AI ") -driven algorithms to enable rapid diagnosis and continuous monitoring of patients with neurological diseases. The Ceribell system makes EEG more accessible and enables continuous monitoring through the power of artificial intelligence, enabling clinicians to diagnose and manage patients at risk of seizures faster and more accurately in acute care settings, thereby improving patient outcomes and economic benefits for hospitals and payers.